JP7261529B1 - Method for producing triazine derivative having virus growth inhibitory action - Google Patents

Abstract

Kind Code: A1 A method for producing a triazine derivative having a novel virus growth inhibitory action is provided. A triazine derivative characterized by reacting a compound represented by the formula (I) TIFF0007261529000068.tif4150 or a salt thereof with a compound represented by the formula (II) TIFF0007261529000069.tif2034 or a salt thereof in the presence of an acid. manufacturing method. [Selection figure] None

Description

The present invention relates to novel compounds exhibiting coronavirus 3CL protease inhibitory activity, novel synthetic intermediates thereof, or salts thereof, and methods for producing them.

Coronaviruses, belonging to the subfamily Orthocoronavirinae of the order Nidoviridae, the family Coronaviridae, have a genome size of approximately 30 kilobases and are the largest known single-stranded +-stranded RNA viruses. Coronaviruses are classified into four genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus, and there are two types of coronaviruses that infect humans: Alphacoronavirus (HCoV-229E, HCoV-229E, HCoV -NL63) and five members of the genus Betacoronavirus (HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, SARS-CoV-2). Of these, four (HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC43) are pathogens of the common cold, while the remaining three are severe acute respiratory syndrome (SARS) coronaviruses that cause severe pneumonia ( SARS-CoV), Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) and novel coronavirus (SARS-CoV-2).

The novel coronavirus infection (COVID-19), which broke out in Wuhan, China in December 2019, rapidly spread throughout the international community, and was declared a pandemic by the WHO on March 11, 2020. As of September 21, 2022, the confirmed number of infected people reached 610 million or more, and the number of deaths reached 6.5 million or more (Non-Patent Document 1). Droplet infection, contact infection and aerosol infection have been reported as the main infection routes of SARS-CoV-2. (Non-Patent Document 2). The incubation period is about 2 to 14 days, and cold-like symptoms such as fever (87.9%), dry cough (67.7%), malaise (38.1%), and phlegm (33.4%) are typical. (Non-Patent Document 3). In severe cases, respiratory failure due to acute respiratory distress syndrome, acute lung injury, interstitial pneumonia, etc. occurs. Multiple organ failure such as renal failure and liver failure has also been reported.

In Japan, from the drug repositioning of existing drugs, the antiviral drug remdesivir, the anti-inflammatory drug dexamethasone, and the antirheumatic drug baricitinib have been approved as therapeutic agents for COVID-19. An additional approval is tocilizumab, a -6 receptor antibody. Also, in July 2021, the antibody cocktail therapy (a combination of anti-SARS-CoV-2 monoclonal antibodies) lonaprive (kasilibimab and imdevimab) will be launched in September 2021 as a single anti-SARS-CoV-2 monoclonal antibody. Zebudi (sotrovimab) was granted special approval, respectively, and mornupiravir was granted special approval in December 2021. Sufficient evidence has not been obtained regarding the efficacy and safety of these drugs and the emergence of resistant strains. Therefore, there is an urgent need to create therapeutic agents against COVID-19.

Ｌｕｆｏｔｒｅｌｖｉｒ（ＰＦ－０７３０４８１４）：

ＰＦ－０７３２１３３２：

さらに２０２１年７月、ハイリスク因子を持つＣＯＶＩＤ－１９患者を対象とした、ＰＦ－０７３２１３３２およびリトナビル併用のＰｈａｓｅ２／３試験が開始されることがＣｌｉｎｉｃａｌＴｒｉａｌｓ．ｇｏｖに掲載された（ＮＣＴ０４９６０２０２）。リトナビルは、ＣＹＰ３Ａによる薬剤の代謝を阻害することにより、薬物動態学的増強因子として働く。また、２０２１年１１月、Ｐｆｉｚｅｒ社のホームページにおいて、ＰＡＸＬＯＶＩＤ（ＴＭ）（ＰＦ－０７３２１３３２；リトナビル）は、成人のハイリスク患者において、プラセボと比較して入院または死亡のリスクを８９％減少させたことが報告された（非特許文献１４）。さらに、２０２１年１２月、ＰＡＸＬＯＶＩＤ（ＴＭ）は米国で緊急使用許可が承認され、２０２２年２月１０日、パキロビッド（登録商標）パックが日本で特例承認された。 When coronaviruses infect cells, they synthesize various proteins required for self-replication. Among them are two polyproteins, the replication complexes that make up the viral genome, and two proteases. Protease plays an essential role in cleaving polyproteins synthesized from viruses and allowing each protein to function. Of the two proteases, 3CL protease (main protease) is responsible for most of the polyprotein cleavage (Non-Patent Document 4).
For COVID-19 therapeutics targeting 3CL protease, in June 2021, Pfizer completed a Phase 1b trial of Lufotrelvir (PF-07304814), a prodrug of PF-00835231, at ClinicalTrials. gov (NCT04535167). Also, in March 2021, Pfizer announced that it will begin Phase 1 trials of PF-07321332, a treatment for COVID-19. The structural formulas of PF-00835231, Lufotrelvir and PF-07321332 are shown below, and have different chemical structures from the compounds produced by the production method according to the present invention (Non-Patent Documents 5, 12 and 13, and Patent Document 6 and 7).
PF-00835231:

Lufotrelvir (PF-07304814):

PF-07321332:

In addition, in July 2021, ClinicalTrials.com announced that a Phase 2/3 trial of PF-07321332 in combination with ritonavir will begin in COVID-19 patients with high-risk factors. gov (NCT04960202). Ritonavir acts as a pharmacokinetic enhancer by inhibiting drug metabolism by CYP3A. Also, in November 2021, Pfizer's website showed that PAXLOVID™ (PF-07321332; ritonavir) reduced the risk of hospitalization or death by 89% compared to placebo in high-risk adults. was reported (Non-Patent Document 14). Additionally, in December 2021, PAXLOVID(TM) was granted emergency use authorization in the United States, and on February 10, 2022, Paxlovid(R) packs were granted special approval in Japan.

Although compounds having 3CL protease inhibitory activity are disclosed in Non-Patent Documents 5 to 8, none of the documents describes or suggests compounds, production methods, and synthetic intermediates related to the present invention.
Triazine and uracil derivatives with _P2X3 and/or P2X2/ ₃ receptor antagonism are disclosed in US Pat. No description or suggestion is made about the effect. Moreover, the production method and synthetic intermediates according to the present invention are neither described nor suggested.
Non-Patent Documents 9 to 11 disclose triazine derivatives having anti-tumor effects, but none of these documents describe coronavirus 3CL protease inhibitory activity and antiviral effects. Relevant compounds, methods of preparation and synthetic intermediates are neither described nor suggested.
Patent document 5 discloses a triazine derivative having galanin receptor modulating activity, but none of the documents describes or suggests 3CL protease inhibitory activity or antiviral effect. Moreover, the production method and synthetic intermediates according to the present invention are neither described nor suggested.

WO2012/020749 WO2013/089212 WO2010/092966 WO2014/200078 WO2012/009258 WO2021/205298 WO2021/250648 Chinese Patent Application Publication No. 113620888 Chinese Patent Application Publication No. 113666914 Chinese Patent Application Publication No. 113735838 Chinese Patent Application Publication No. 113773300 Chinese Patent Application Publication No. 113801097

“COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns Hopkins University”, [online], Johns Hopkins University, [searched September 21, 2022], Internet <URL: https://coronavirus.jhu.edu /map.html> The NEW ENGLAND JOURNAL of MEDICINE (2020), Volume 382, Pages 1564-1567 "Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)", [online], February 28, 2020, WHO, [searched September 21, 2022], Internet <URL: https:/ /www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> Science (2003), vol.300, pp.1763-1767 “A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19”, Journal of Virology, [online], February 23, 2021, [September 21, 2022] Search], Internet <URL: https://jvi.asm.org/content/early/2021/02/19/JVI.01819-20><doi: 10.1128/JVI.01819-20> Cell Research (2020), vol.30, pp.678-692 Science (2020), vol.368, pp.409-412 ACS Central Science (2021), Vol. 7, No. 3, pp. 467-475 Cancer Treatment Reviews (1984), Vol. 11, Supplement 1, pp. 99-110. Contributions to Oncology (1984) 18:221-234 Arzneimittel-Forschung (1984), Vol. 11, No. 6, pp. 663-668. 261st Am Chem Soc (ACS) Natl Meet ・ 2021-04-05 / 2021-04-16 ・ Virtual, N/A ・ Abst 243 Science (2021), vol.374, pp.1586-1593 "Pfizer's Novel COVID-19 Oral Antiviral Treatment Candidate Reduced Risk Of Hospitalization Or Death By 89% In Interim Analysis Of Phase 2/3 EPIC-HR Study," [online], 5 November 2021, Pfizer Press Release, [2022] Searched September 21, 2019], Internet <URL: https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate>

An object of the present invention is to provide novel synthetic intermediates of novel compounds having coronavirus 3CL protease inhibitory activity or salts thereof, and production methods.

（式中、Ｒ^１は置換もしくは非置換のＣ１－Ｃ４アルキル、Ｒ^２はそれぞれ独立して、ハロゲン、シアノまたはメチル、ｎは１～５の整数である。）で示される化合物またはその塩と、式（ＩＩ）：

（式中、Ｒ^３はそれぞれ独立して、置換もしくは非置換のＣ１－Ｃ４アルキル、ｍは０～５の整数である）で示される化合物またはその塩を、酸存在下で反応させることを特徴とする、式（ＩＩＩ）：

で示される化合物またはその塩の製造方法。
（２）酸が、トリフルオロ酢酸である、上記（１）記載の製造方法。
（３）式（ＩＩＩ）で示される化合物が、式（ＩＩＩ－１）：

である、上記（１）または（２）記載の製造方法。
（４）式（ＩＶ）：

（式中、Ｒ^４は置換もしくは非置換の芳香族複素環式基、または置換もしくは非置換の芳香族炭素環式基であり、ｐは０または１であり、その他の記号は上記（１）と同意義である。）で示される化合物またはその塩と、式（Ｖ）：

（式中、Ｒ^５はそれぞれ独立して、ハロゲン、または置換もしくは非置換のアルキルであり、ｑは０～５の整数である。）で示される化合物またはその塩を、酸存在下で反応させることを特徴とする、式（ＶＩ）：

（式中の記号は上記と同意義である。）で示される化合物、その塩またはそれらの溶媒和物の製造方法。
（５）酸が酢酸である、上記（４）記載の製造方法。
（６）式（ＶＩ）で示される化合物が、
式（ＶＩＩ）：

である、上記（４）または（５）記載の製造方法。
（７）上記（１）～（３）のいずれかの製造方法より、式（ＩＩＩ－１）：

で示される化合物またはその塩を得る工程を含む、式（ＶＩＩ）：

で示される化合物、その塩またはそれらの溶媒和物の製造方法。
（８）式（ＶＩＩ）：

で示される化合物またはその塩を、フマル酸、アセトンおよび水存在下で結晶化することを特徴とする、式（ＶＩＩ）で示される化合物のフマル酸共結晶Ｉ形の製造方法。
（９）上記（１）～（７）のいずれかに記載の製造方法を使用することにより得られた式（ＶＩＩ）：

で示される化合物またはその塩を、結晶化させることを特徴とする、上記（８）記載の製造方法。
（１０）結晶化温度が４０～６０℃であり、結晶化時間が１２０分以上である、上記（８）または（９）記載の製造方法。
（１１）式（ＶＩＩＩ）：

で示される化合物、またはその塩。
（１２）式（ＩＸ）：

で示される化合物、またはその塩。
（１３）式（Ｘ）：

で示される化合物、またはその塩。
（１４）式（ＸＩ）：

で示される化合物、またはその塩。
（１５）式（ＶＩＩ）：

で示される化合物のトルエン和物。
（１６）実質的に、式（ＶＩＩ）：

で示される化合物のフリー体が含まれない、式（ＶＩＩ）で示される化合物のフマル酸共結晶Ｉ形。
（１７）以下の式：

で示される化合物のメシル酸塩。
（１８）以下の式：

で示される化合物のメシル酸塩。
（１９）以下の式：

で示される化合物、またはその塩。
（２０）以下の式：

で示される化合物、またはその塩。
（２１）以下の式：

で示される化合物の１，８－ジアザビシクロ［５．４．０］－７－ウンデセン塩である、上記項目（２０）記載の塩。 The present invention relates to the following.
(1) Formula (I):

(wherein R ¹ is substituted or unsubstituted C1-C4 alkyl, R ² is each independently halogen, cyano or methyl, and n is an integer of 1 to 5) or a salt thereof , formula (II):

(Wherein, each R ³ is independently a substituted or unsubstituted C1-C4 alkyl, and m is an integer of 0 to 5) or a salt thereof is reacted in the presence of an acid. and formula (III):

A method for producing a compound represented by or a salt thereof.
(2) The production method according to (1) above, wherein the acid is trifluoroacetic acid.
(3) The compound represented by formula (III) is represented by formula (III-1):

The production method according to (1) or (2) above.
(4) Formula (IV):

(Wherein, R ⁴ is a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted aromatic carbocyclic group, p is 0 or 1, and other symbols are the above (1) and a compound represented by or a salt thereof represented by the formula (V):

(Wherein, each R ⁵ is independently a halogen or a substituted or unsubstituted alkyl, and q is an integer of 0 to 5) or a salt thereof is reacted in the presence of an acid. Formula (VI), characterized in that:

(The symbols in the formula have the same meanings as above.) A method for producing a compound represented by the formula, a salt thereof, or a solvate thereof.
(5) The production method according to (4) above, wherein the acid is acetic acid.
(6) a compound represented by formula (VI),
Formula (VII):

The production method according to (4) or (5) above.
(7) Formula (III-1):

A step of obtaining a compound of formula (VII) or a salt thereof:

A method for producing a compound represented by, a salt thereof, or a solvate thereof.
(8) Formula (VII):

or a salt thereof in the presence of fumaric acid, acetone and water.
(9) Formula (VII) obtained by using the production method described in any one of (1) to (7) above:

The production method according to (8) above, wherein the compound represented by or a salt thereof is crystallized.
(10) The production method according to (8) or (9) above, wherein the crystallization temperature is 40 to 60° C. and the crystallization time is 120 minutes or longer.
(11) Formula (VIII):

A compound represented by or a salt thereof.
(12) Formula (IX):

A compound represented by or a salt thereof.
(13) Formula (X):

A compound represented by or a salt thereof.
(14) Formula (XI):

A compound represented by or a salt thereof.
(15) Formula (VII):

Toluene solute of the compound represented by.
(16) Substantially Formula (VII):

Fumaric acid co-crystal form I of the compound of formula (VII), which does not contain the free form of the compound of formula (VII).
(17) the following formula:

The mesylate salt of the compound represented by
(18) the following formula:

The mesylate salt of the compound represented by
(19) the following formula:

A compound represented by or a salt thereof.
(20) the following formula:

A compound represented by or a salt thereof.
(21) the following formula:

The salt according to item (20) above, which is a 1,8-diazabicyclo[5.4.0]-7-undecene salt of the compound represented by

The compound produced by the production method according to the present invention has inhibitory activity against coronavirus 3CL protease, and is useful as a therapeutic and/or preventive agent for coronavirus infection.
Moreover, the compound produced by the production method according to the present invention is useful as a drug substance.
Furthermore, a pharmaceutical composition containing the fumaric acid co-crystal of the compound represented by formula (VII) produced by the production method according to the present invention is very useful as a therapeutic agent for novel coronavirus infection (COVID-19). is. The production method according to the present invention is a method capable of producing the compound according to the present invention in good yield.

Figure 2 shows a structural diagram in the asymmetric unit of fumaric acid co-crystal Form I of the compound of formula (VII). 1 shows the powder X-ray diffraction pattern of fumaric acid co-crystal Form I of the compound of formula (VII). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count). 1 shows a powder X-ray diffraction pattern of the toluene solute of the compound represented by formula (VII). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).

The meaning of each term used in this specification will be explained below. Unless otherwise specified, each term has the same meaning whether it is used alone or in combination with other terms.
The term "consisting of" means having only constituent elements.
The term "comprising" is meant to be open to the elements and does not exclude elements not listed.
Hereinafter, the present invention will be described while showing embodiments. It should be understood that throughout this specification, expressions in the singular also include the concept of the plural unless specifically stated otherwise. Thus, articles in the singular (eg, “a,” “an,” “the,” etc. in the English language) should be understood to include their plural forms as well, unless otherwise stated.
In addition, it should be understood that the terms used in this specification have the meanings commonly used in the art unless otherwise specified. Thus, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification (including definitions) will control.

"Halogen" includes fluorine, chlorine, bromine and iodine atoms. Fluorine and chlorine atoms are particularly preferred.

"Alkyl" includes a linear or branched hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, still more preferably 1 to 4 carbon atoms. do. For example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl , isooctyl, n-nonyl, n-decyl and the like.
Preferred embodiments of "alkyl" include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and n-pentyl. More preferred embodiments include methyl, ethyl, n-propyl, isopropyl and tert-butyl.
"C1-C4 alkyl" includes a straight chain or branched hydrocarbon group having 1 to 4 carbon atoms. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl and the like.

An “aromatic carbocyclic group” means a monocyclic or bicyclic or more cyclic aromatic hydrocarbon group. Examples include phenyl, naphthyl, anthryl, phenanthryl and the like. Six-membered aromatic carbocyclic groups include, for example, phenyl. Examples of 10-membered aromatic carbocyclic groups include naphthyl and the like. Examples of 14-membered aromatic carbocyclic groups include anthryl, phenanthryl and the like.
A preferred embodiment of the "aromatic carbocyclic group" is phenyl.

"Aromatic carbocyclic ring" means a ring derived from the above "aromatic carbocyclic group".

“Aromatic heterocyclic group” means a monocyclic or bicyclic or more aromatic cyclic group having one or more heteroatoms which are the same or different and are arbitrarily selected from O, S and N in the ring. do.
An aromatic heterocyclic group with two or more rings includes a monocyclic or an aromatic heterocyclic group with two or more rings condensed with the ring in the above "aromatic carbocyclic group", and the bond is Either ring may have it.
The monocyclic aromatic heterocyclic group is preferably 5- to 8-membered, more preferably 5- or 6-membered. Five-membered aromatic heterocyclic groups include, for example, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl and the like. Examples of 6-membered aromatic heterocyclic groups include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
The bicyclic aromatic heterocyclic group is preferably 8- to 10-membered, more preferably 9- or 10-membered. For example, indolyl, isoindolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl. Ryl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridyl, thiazolopyridyl, etc. is mentioned. 9-membered aromatic heterocyclic groups include indolyl, isoindolyl, indazolyl, indolizinyl, purinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazo lyl, benzotriazolyl, benzofuranyl, imidazopyridyl, triazolopyridyl, oxazolopyridyl, thiazolopyridyl and the like. Ten-membered aromatic heterocyclic groups include quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, pteridinyl, pyrazinopyridazinyl, and the like.
The aromatic heterocyclic group having 3 or more rings is preferably 13- to 15-membered. Examples include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl and the like.
A preferred embodiment of the "aromatic heterocyclic group" is triazolyl.

"Heteroaromatic ring" means a ring derived from the above "heteroaromatic group".

Substituents of "substituted alkyl" include the following Substituent Group A. A carbon atom at any position may be bonded to one or more groups selected from Substituent Group A below.
Substituent group A: halogen, cyano and nitro.
Substituents of the “substituted C1-C4 alkyl” include the following Substituent Group B. A carbon atom at any position may be bonded to one or more groups selected from Substituent Group B below.
Substituent group B: halogen, cyano and nitro.

As substituents on the ring of "aromatic carbocyclic ring" and "aromatic heterocyclic ring" such as "substituted aromatic carbocyclic group" and "substituted aromatic heterocyclic group", the following substituent group C mentioned. An atom at any position on the ring may be bonded to one or more groups selected from Substituent Group B below.
Substituent group C: halogen, cyano, nitro and alkyl.

例えば、式（ＶＩＩ）で示される化合物は、以下のような互変異性体を包含する。

The compounds of formula (VI) and formula (VII) are not limited to any particular isomer, but all possible isomers (e.g. keto-enol isomers, imine-enamine isomers, diastereoisomers isomers, optical isomers, rotational isomers, etc.), racemates or mixtures thereof.

For example, compounds of formula (VII) include the following tautomers.

で示される化合物のフリー体が含まれない、式（ＶＩＩ）で示される化合物のフマル酸共結晶Ｉ形とは、粉末Ｘ線回折測定等の測定機器で、式（ＶＩＩ）で示される化合物のフリー体由来のピークが検出されない（検出限界以下である）、式（ＶＩＩ）で示される化合物のフマル酸共結晶Ｉ形を意味する。 Substantially the formula (VII):

The fumaric acid co-crystal form I of the compound represented by formula (VII), which does not contain the free form of the compound represented by, is a measuring instrument such as powder X-ray diffraction measurement of the compound represented by formula (VII). It means the fumaric acid co-crystal Form I of the compound represented by the formula (VII) in which no peak derived from the free form is detected (below the detection limit).

Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX ), one or more hydrogen, carbon and/or other atoms of the compounds of formula (X) and formula (XI) may be substituted with isotopes of hydrogen, carbon and/or other atoms, respectively. Examples of such isotopes include ² H, ³ H, ¹¹ C, ¹³ C, ¹⁴ C, ¹⁵ N, ¹⁸ O, ¹⁷ O ^, 31 P, ³² P, ³⁵ S, ¹⁸ F, ¹²³ I and Hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine and chlorine are included, as is ³⁶ Cl. Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX ), formula (X), and formula (XI) also include such isotopically substituted compounds. The isotope-substituted compounds are also useful as pharmaceuticals, and are represented by formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula It includes all radiolabeled compounds of formula (VI), formula (VII), formula (VIII), formula (IX), formula (X) and formula (XI). A "radiolabeling method" for producing the "radiolabel" is also encompassed by the present invention, and the "radiolabel" is useful as a research and/or diagnostic tool in metabolic pharmacokinetic studies, binding assays. is.
Also, the crystal according to the present invention may be a deuterium converter. Crystals according to the present invention may be labeled with isotopes (eg, ³ H, ¹⁴ C, ³⁵ S, ¹²⁵ I, etc.).

Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX ), the radiolabeled compounds of formulas (X) and (XI) can be prepared by methods well known in the art. For example, formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula The tritium-labeled compounds represented by (IX), formula (X) and formula (XI) are obtained by introducing tritium into the specific compound represented by formula (I) by catalytic dehalogenation reaction using tritium. can be prepared. This method is carried out in the presence or absence of a base in the presence of a suitable catalyst such as Pd/C, formula (I), formula (II), formula (III), formula (III-1), formula ( IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX), Formula (X) and Formula (XI) are suitably halogen-substituted precursors and tritium gas. Other suitable methods for preparing tritiated compounds can be found in "Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987)". ¹⁴ C-labeled compounds can be prepared by using starting materials with a ¹⁴ C carbon.

Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Formula (IX ), and the salts of the compounds represented by formulas (X) and (XI) include, for example, formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), a compound represented by formula (VI), formula (VII), formula (VIII), formula (IX), formula (X) and formula (XI) and an alkali metal (e.g., lithium, sodium, potassium, etc.) ), alkaline earth metals (e.g., calcium, barium, etc.), magnesium, transition metals (e.g., zinc, iron, etc.), ammonia, organic bases (e.g., trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine , meglumine, ethylenediamine, pyridine, picoline, quinoline, etc.) and salts with amino acids, inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid, etc.), and organic acids (e.g. formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, succinic acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid , benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, trifluoroacetic acid, etc.). These salts can be formed by a commonly used method.
A salt of a compound of formula (VII) consists, for example, of a compound of formula (VII) and a counter molecule or counter ion, and may contain any number of counter molecules or counter ions. A salt of a compound represented by formula (VII) refers to one through an ionic bond by proton transfer between the compound and a counter molecule or counter atom.

Formula (I) of the present invention, formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), Compounds of formula (IX), formula (X) and formula (XI) or salts thereof may form solvates (e.g., hydrates, etc.), co-crystals and/or polymorphs, The invention also includes various such solvates, co-crystals and polymorphs. "Solvate" refers to Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula The compounds represented by (VIII), formula (IX), formula (X) and formula (XI) may be coordinated with any number of solvent molecules (eg, water molecules, etc.). Further, formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula Compounds of formula (IX), formula (X) and formula (XI) or salts thereof may be recrystallized to form polymorphs.

As used herein, the term "crystal" means a solid in which constituent atoms, ions, molecules, etc. are arranged regularly in three dimensions, and is distinguished from amorphous solids that do not have such a regular internal structure. be. Crystals according to the present invention may be single crystals, twin crystals, polycrystals, and the like.
Furthermore, "crystals" may have "crystal polymorphs" that have the same composition but different arrangements in the crystal, and these are collectively referred to as "crystal forms".
In addition, Formula (I), Formula (II), Formula (III), Formula (III-1), Formula (IV), Formula (V), Formula (VI), Formula (VII), Formula (VIII), Compounds of formula (IX), formula (X) and formula (XI) may be converted into salts or pharmaceutically acceptable solvates thereof. The crystals according to the present invention may be any of salts, hydrates, solvates, and crystal polymorphs thereof, and mixtures of two or more thereof are also included within the scope of the invention. intended.
Crystalline morphology and crystallinity can be measured by a number of techniques including, for example, powder X-ray diffraction measurements, Raman spectroscopy, infrared spectroscopy, moisture adsorption-desorption measurements, differential scanning calorimetry, dissolution properties. can.

As used herein, "co-crystal" means, for example, that the compound represented by formula (VII) and the counter molecule are regularly arranged in the same crystal lattice, including any number of counter molecules. You can stay A co-crystal refers to an intermolecular interaction between a compound and a counter molecule through non-covalent and non-ionic chemical interactions such as hydrogen bonding and van der Waals forces. Co-crystals are distinguished from salts in that the compounds remain essentially uncharged or neutral. Co-crystals are distinguished from hydrates or solvates in that the counter-molecule is not water or solvent.

Complexes comprising compounds of formula (VII) of the present invention broadly include salts, co-crystals and clathrates, or solvates thereof.

As used herein, "solvate" refers to, for example, formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula (VI ), Formula (VII), Formula (VIII), Formula (IX), Formula (X), and Formula (XI), which are regularly arranged with any number of solvent molecules.
Solvent molecules include, for example, acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane , 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutylketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethene , xylene, acetic acid, anisole, 1-butanol, 2-butanol, n-butyl acetate, t-butyl methyl ether, cumene, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, Methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, water (i.e. hydrated substance), ethanol, acetone, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyltetrahydrofuran, petroleum ether, trichloroacetic acid and trifluoroacetic acid , preferably acetic acid, anisole, 1-butanol, 2-butanol, n-butyl acetate, t-butyl methyl ether, cumene, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate , methyl acetate, 3-methyl-1-butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, water (i.e. water hydrate), ethanol, acetone, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyltetrahydrofuran, petroleum ether, trichloroacetic acid and trifluoro Acetic acid, more preferably water (i.e. hydrates), ethanol, acetone, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl Tetrahydrofuran, petroleum ether, trichloroacetic acid and trifluoroacetic acid, and the like.
Further, formula (I), formula (II), formula (III), formula (III-1), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula When the compounds represented by (IX), formula (X) and formula (XI), or salts, co-crystals and complexes thereof, are left in the air, they absorb water and adhere to the adsorbed water, May form hydrates.

(X-ray powder diffraction (XRPD))
X-ray powder diffraction (XRPD) is one of the most sensitive analytical methods for determining the crystalline form and crystallinity of solids. When the crystal is irradiated with X-rays, they are reflected at the crystal lattice planes, interfere with each other, and exhibit ordered diffraction lines corresponding to the period of the structure. On the other hand, amorphous solids usually do not have an ordered repeating period in their structure, so diffraction phenomena do not occur and they exhibit featureless broad XRPD patterns (also called halo patterns).

Crystalline forms of the compound of formula (VII) are distinguishable by powder X-ray diffraction patterns and characteristic diffraction peaks. The crystalline form of the compound of formula (VII) can be distinguished from other crystalline forms by the presence of characteristic diffraction peaks.
A characteristic diffraction peak, as used herein, is a peak selected from an observed diffraction pattern. The characteristic diffraction peaks are preferably selected from about 10, more preferably about 5, even more preferably about 3 in the diffraction pattern.
In order to distinguish a plurality of crystals, rather than the intensity of the peak, the peak that is confirmed in the crystal and not confirmed in other crystals is a characteristic peak that is preferable for identifying the crystal. One or even two such characteristic peaks can characterize the crystal. If the charts obtained by the measurements are compared and these characteristic peaks match, it can be said that the powder X-ray diffraction spectra substantially match.

In general, the diffraction angle (2θ) in powder X-ray diffraction can have an error within the range of ±0.2°, so the value of the diffraction angle in powder X-ray diffraction is within the range of about ±0.2°. should be understood as including Therefore, the present invention includes not only crystals in which the diffraction angles of peaks in powder X-ray diffraction completely match, but also crystals in which the diffraction angles of peaks match with an error of about ±0.2°.

The intensity of the peaks displayed in the tables and figures below generally depends on many factors, such as the effect of the preferred orientation of the crystals on the X-ray beam, the effect of coarse grains, the purity of the material being analyzed or the crystallinity of the sample. known to be variable. Peak positions may also shift based on variations in sample height. Furthermore, although measurements using different wavelengths give different shifts according to the Bragg equation (nλ=2d sin θ), compounds with different XRPD patterns obtained by using such different wavelengths are also within the scope of the present invention. include.

(Single crystal structure analysis)
It is one of the methods for identifying a crystal, and it is possible to obtain crystallographic parameters of the crystal, as well as atomic coordinates (values indicating the spatial positional relationship of each atom) and a three-dimensional structure model. See Toshio Sakurai, "Guide to X-Ray Structural Analysis," published by Shokabo (1983), Stout & Jensen, X-Ray Structure Determination: A Practical Guide, Macmillan Co., New York (1968). Single crystal structure analysis is useful for identifying the crystal structures of the complexes, salts, optical isomers, tautomers, and geometric isomers of the present invention.

Since the compound produced by the production method according to the present invention has coronavirus 3CL protease inhibitory activity, it is useful as a therapeutic and/or preventive agent for diseases associated with coronavirus 3CL protease. The term "therapeutic agent and/or prophylactic agent" as used herein also includes symptom-improving agents. Diseases involving coronavirus 3CL protease include viral infections, preferably coronavirus infections.
In one embodiment, coronaviruses include coronaviruses that infect humans. Coronaviruses that infect humans include HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and/or SARS-CoV-2.
In one embodiment, coronaviruses include alphacoronaviruses and/or betacoronaviruses, more preferably betacoronaviruses.
In one aspect, alphacoronaviruses include HCoV-229E and HCoV-NL63. Particularly preferred is HCoV-229E.
In one aspect, betacoronaviruses include HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and/or SARS-CoV-2. HCoV-OC43 or SARS-CoV-2 is preferred, and SARS-CoV-2 is particularly preferred.
In one embodiment, the betacoronavirus includes betacoronavirus A strain (β-coronavirus lineage A), betacoronavirus B strain (β-coronavirus lineage B), and betacoronavirus C strain (β-coronavirus lineage C). is mentioned. More preferred are β-coronavirus lineage A and β-coronavirus lineage B, particularly preferably β-coronavirus lineage B.
In one embodiment, the betacoronavirus includes the subgenus Sarbecovirus.
Betacoronavirus lineage A includes, for example, HCoV-HKU1 and HCoV-OC43, preferably HCoV-OC43. Betacoronavirus lineage B includes, for example, SARS-CoV and SARS-CoV-2, preferably SARS-CoV-2. The beta-coronavirus lineage C preferably includes MERS-CoV.
In one embodiment, coronaviruses include HCoV-229E, HCoV-OC43 and/or SARS-CoV-2, particularly preferably SARS-CoV-2.
Coronavirus infections include infections by HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV, MERS-CoV, and/or SARS-CoV-2. Preferred are infections caused by HCoV-229E, HCoV-OC43 and/or SARS-CoV-2, particularly preferably infections caused by SARS-CoV-2.
A novel coronavirus infection (COVID-19) is particularly preferred as the coronavirus infection.

式中の記号は上記と同意義である。
本工程は、式（Ｉ）で示される化合物と式（ＩＩ）で示される化合物を酸存在下で反応させることを特徴とする、式（ＩＩＩ）で示される化合物の製造方法である。
式（Ｉ）で示される化合物に対して、式（ＩＩ）で示される化合物は、通常、１．０～５．０当量、例えば、１．０～３．０当量用いることができる。
溶媒としては、上記工程を効率よく進行させるものであれば特に制限されず、酸を溶媒として利用してもよい。酸、トルエン、塩化メチレン、ジクロロエタン等が挙げられ、単独または混合して用いることができる。好ましくは、酸が挙げられる。
酸としては、プロトン酸、ルイス酸が挙げられ、好ましくは、トリフルオロ酢酸が挙げられる。
式（Ｉ）で示される化合物に対して、酸の使用量は通常、１．０当量～大過剰、例えば、５．０当量～大過剰用いることができる。
反応温度は、特に制限されないが通常、約０℃～約５０℃、好ましくは、室温～４０℃で行うことができる。
反応時間は、特に制限されないが通常、０．１時間～１２時間、好ましくは、０．１～５時間である。 A manufacturing method according to the present invention will be described below.
Step 1 Method for producing a compound represented by formula (III)

The symbols in the formula have the same meanings as above.
This step is a method for producing a compound represented by formula (III), characterized by reacting a compound represented by formula (I) with a compound represented by formula (II) in the presence of an acid.
The compound represented by formula (II) can be used usually in an amount of 1.0 to 5.0 equivalents, for example 1.0 to 3.0 equivalents, relative to the compound represented by formula (I).
The solvent is not particularly limited as long as it allows the above steps to proceed efficiently, and an acid may be used as the solvent. Acid, toluene, methylene chloride, dichloroethane and the like can be mentioned and can be used singly or in combination. Acids are preferred.
Acids include protonic acids and Lewis acids, preferably trifluoroacetic acid.
The amount of the acid to be used is generally 1.0 equivalents to large excess, for example 5.0 equivalents to large excess, relative to the compound represented by formula (I).
Although the reaction temperature is not particularly limited, it can be usually carried out at about 0°C to about 50°C, preferably room temperature to 40°C.
Although the reaction time is not particularly limited, it is usually 0.1 to 12 hours, preferably 0.1 to 5 hours.

式中の記号は上記と同意義である。
本工程は、式（ＩＶ）で示される化合物と式（Ｖ）で示される化合物を酸存在下で反応させることを特徴とする、式（ＶＩ）で示される化合物の製造方法である。
式（ＩＶ）で示される化合物に対して、式（Ｖ）で示される化合物は、通常、１．０～５．０当量、例えば、１．０～１．５当量用いることができる。
溶媒としては、上記工程を効率よく進行させるものであれば特に制限されず、酸を溶媒として利用してもよい。トルエン、ｔブタノール、ｔアミルアルコール等が挙げられ、単独または混合して用いることができる。好ましくは、トルエン挙げられる。
酸としては、酢酸、２，２―ジメチルブタン酸等が挙げられる。好ましくは、酢酸が挙げられる。
式（ＩＶ）で示される化合物に対して、酸の使用量は通常、１．０当量～１０当量、例えば、３．０当量～１０当量用いることができる。
反応温度は、特に制限されないが通常、室温～約１５０℃またはマイクロウェーブ照射下、好ましくは、５０～１５０℃またはマイクロウェーブ照射下で行うことができる。
反応時間は、特に制限されないが通常、０．１時間～１２時間、好ましくは、３～１０時間である。 Step 2: Method for producing a compound represented by formula (VI)

The symbols in the formula have the same meanings as above.
This step is a method for producing a compound represented by formula (VI), characterized by reacting a compound represented by formula (IV) with a compound represented by formula (V) in the presence of an acid.
The compound represented by formula (V) can be used generally in an amount of 1.0 to 5.0 equivalents, for example 1.0 to 1.5 equivalents, relative to the compound represented by formula (IV).
The solvent is not particularly limited as long as it allows the above steps to proceed efficiently, and an acid may be used as the solvent. Toluene, t-butanol, t-amyl alcohol and the like can be mentioned, and can be used alone or in combination. Toluene is preferred.
Acids include acetic acid, 2,2-dimethylbutanoic acid and the like. Acetic acid is preferred.
The amount of acid to be used is generally 1.0 to 10 equivalents, for example, 3.0 to 10 equivalents, relative to the compound represented by formula (IV).
The reaction temperature is not particularly limited, but usually room temperature to about 150° C. or under microwave irradiation, preferably 50 to 150° C. or under microwave irradiation.
Although the reaction time is not particularly limited, it is usually 0.1 to 12 hours, preferably 3 to 10 hours.

Step 3 Method for producing fumaric acid co-crystal Form I of the compound of formula (VII) This step is characterized by crystallizing the compound of formula (VII) in the presence of fumaric acid, acetone and water. , a process for preparing the fumaric acid co-crystal Form I of the compound of formula (VII).
The amount of fumaric acid to be used is generally 1.0 to 3.0 equivalents, for example, 1.0 to 1.5 equivalents, relative to the compound represented by formula (VII).
Although the crystallization temperature is not particularly limited, it is usually 40 to 80°C, preferably 40 to 60°C.
Although the crystallization time is not particularly limited, it is usually 1 hour or longer, preferably 2 hours or longer, and more preferably 2 to 12 hours.
The reaction may be carried out in the presence of acetone and water, preferably at a ratio of acetone and water of 85:15 to 50:50.

The compound (compound represented by formula (VII)) produced by the production method according to the present invention has coronavirus 3CL protease inhibitory activity and is therefore useful as a therapeutic and/or prophylactic agent for viral infections.
Furthermore, the compound produced by the production method according to the present invention is useful as a medicine, and preferably has one or more of the following excellent characteristics.
a) It has a weak inhibitory effect on CYP enzymes (eg, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, etc.).
b) shows good pharmacokinetics such as high bioavailability and moderate clearance;
c) high metabolic stability;
d) Does not exhibit irreversible inhibitory action on CYP enzymes (eg, CYP3A4) within the concentration range of the measurement conditions described herein.
e) not mutagenic;
f) low cardiovascular risk;
g) exhibit high solubility;
h) High protein non-binding rate (fu value).
i) have high coronavirus 3CL protease selectivity;
j) It has high coronavirus growth inhibitory activity. For example, it has high coronavirus growth inhibitory activity under the addition of human serum (HS) or human serum albumin (HSA).
Examples of coronavirus growth inhibitors include embodiments in which EC ₅₀ is 10 μM or less, preferably 1 μM or less, and more preferably 100 nM or less in the CPE suppression effect confirmation test (SARS-CoV-2) described later.
In addition, the salt, crystal, complex, or co-crystal of the compound produced by the production method according to the present invention has usefulness as a medicine, and preferably exhibits one or more of the following excellent characteristics: have.
bb) It exhibits good pharmacokinetics, such as high bioavailability, moderate clearance, high AUC, and high peak blood concentration.
gg) exhibit high solubility, high chemical stability and low hygroscopicity;

A pharmaceutical composition containing a compound produced by the production method according to the present invention can be administered either orally or parenterally. Examples of parenteral administration methods include transdermal, subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, transmucosal, inhalation, nasal, ocular, ear and intravaginal administration.

For oral administration, internal solid preparations (e.g., tablets, powders, granules, capsules, pills, films, etc.), internal liquid preparations (e.g., suspensions, emulsions, elixirs, syrups, etc.) It may be prepared and administered in any commonly used dosage form such as a drug, limonade, alcohol, aromatic water, extract, decoction, tincture, and the like. Tablets may be sugar-coated tablets, film-coated tablets, enteric-coated tablets, sustained-release tablets, troches, sublingual tablets, buccal tablets, chewable tablets or orally disintegrating tablets, and powders and granules may be dry syrups. Alternatively, the capsules may be soft capsules, microcapsules or sustained release capsules.

In the case of parenteral administration, injections, drops, external preparations (e.g., eye drops, nasal drops, ear drops, aerosols, inhalants, lotions, injections, coatings, gargles, enemas, Any commonly used dosage form such as ointments, plasters, jellies, creams, patches, poultices, powders for external use, suppositories, etc.) can be suitably administered. Injections may be emulsions such as O/W, W/O, O/W/O and W/O/W types.

An effective amount of the compound produced by the production method according to the present invention is mixed with various pharmaceutical additives such as excipients, binders, disintegrants, lubricants, etc. suitable for the dosage form, if necessary, and the drug is obtained. It can be a composition. Further, the pharmaceutical composition can be prepared for pediatric, elderly and critically ill patients by appropriately changing the effective amount, dosage form and/or various pharmaceutical additives of the compound produced by the production method according to the present invention. Alternatively, it can be a pharmaceutical composition for surgery. For example, a pediatric pharmaceutical composition can be used for neonates (less than 4 weeks after birth), infants (4 weeks after birth to less than 1 year old) infants (1 to 7 years old), children (7 to 15 years old) or 15 Patients between the ages of 18 and 18 can be administered. For example, geriatric pharmaceutical compositions may be administered to patients 65 years of age or older.

The dosage of the pharmaceutical composition containing the compound produced by the production method of the present invention (for example, the pharmaceutical composition containing the fumaric acid cocrystal form I of the compound represented by formula (VII)) depends on the age of the patient, It is desirable to set the dosage in consideration of body weight, type and degree of disease, route of administration, etc. In the case of oral administration, it is usually 0.05 to 200 mg/kg/day, preferably 0.1 to 100 mg/kg. / days. In the case of parenteral administration, it is generally 0.005 to 200 mg/kg/day, preferably 0.01 to 100 mg/kg/day, although it varies greatly depending on the route of administration. It may be administered once to several times a day.

The compound (compound represented by formula (VII)) produced by the production method according to the present invention is used for the purpose of enhancing the action of the compound or reducing the dosage of the compound, for example, other novel coronavirus infections It may be used in combination with a therapeutic drug for disease (COVID-19) (the therapeutic drug includes an approved drug and a drug under development or to be developed in the future) (hereinafter referred to as a concomitant drug). In this case, the timing of administration of the compound produced by the production method of the present invention and the concomitant drug are not limited, and they may be administered to the subject at the same time or at different times. Furthermore, the compound produced by the production method according to the present invention and the concomitant drug may be administered as two or more formulations containing each active ingredient, or administered as a single formulation containing those active ingredients. may be

The dose of the concomitant drug can be appropriately selected based on the clinically used dose. In addition, the compounding ratio of the compound produced by the production method of the present invention and the concomitant drug can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination, and the like. For example, when the subject of administration is a human, 0.01 to 100 parts by weight of the concomitant drug may be used with respect to 1 part by weight of the compound produced by the production method according to the present invention.

EXAMPLES The present invention will be described in more detail below with reference to Examples, Reference Examples, and Test Examples, but the present invention is not limited thereto.

Abbreviations used in this specification have the following meanings.
BINAP: 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl Boc: tert-butoxycarbonyl CPME: cyclopentyl methyl ether CbzCl: benzyl chloroformate DME: dimethyl ether DMF: N,N-dimethylformamide DMSO: Dimethylsulfoxide DTT: Dithiothreitol EDC: 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide EDT: 1,2-ethanedithiol EDTA: Ethylenediaminetetraacetic acid FBS: Fetal bovine serum HOBT: 1-Hydroxybenzotriazole LHMDS: Lithium bis(trimethylsilyl)amide MEK: methyl ethyl ketone MEM: Eagle's minimum essential medium NMP: N-methyl-2-pyrrolidone TFA: trifluoroacetic acid TMSCl: chlorotrimethylsilane mM: mmol/L
μM: μmol/L
nM: nmol/L

(Compound identification method)
NMR analysis obtained in each example and reference example was performed at 400 MHz and measured using DMSO-d ₆ and CDCl ₃ . Moreover, when NMR data are shown, there are cases where not all measured peaks are shown.
"RT" or "retention time" in the specification represents retention time in LC/MS: liquid chromatography/mass spectrometry or liquid chromatography, and was measured under the following conditions.
In the specification, the description of MS (m/z) indicates the value observed by mass spectrometry.
(Measurement condition 1)
Column: ACQUITY UPLC® BEH C18 (1.7 μm id 2.1×50 mm) (Waters)
Flow rate: 0.8 mL/min UV detection wavelength: 254 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile solution containing 0.1% formic acid Gradient: After performing a linear gradient of 5%-100% solvent [B] in 3.5 minutes , 100% solvent [B] was maintained for 0.5 min.
(Measurement condition 2)
Column: ACQUITY UPLC® BEH C18 (1.7 μm id 2.1×50 mm) (Waters)
Flow rate: 0.8 mL/min UV detection wavelength: 254 nm
Mobile phase: [A] is an aqueous solution containing 10 mM ammonium carbonate, [B] is an acetonitrile solution containing 0.1% formic acid. Maintain 100% solvent [B] for .5 minutes.
(Measurement condition 4)
Column: Xselect CSH C18 (3.5 μm id 4.6×150 mm) (Waters)
Column temperature: constant temperature around 40°C UV detection wavelength: 254 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile gradient for liquid chromatography: 5%-95% solvent [B] linear gradient in 17 minutes, followed by 3 minutes, 95 % solvent [B] was maintained.
Flow rate: 1.0 mL/min Injection volume: 5 μL
(Measurement condition 5)
Column: Xselect CSH C18 (3.5 μm id 4.6×150 mm) (Waters)
Column temperature: constant temperature around 40°C UV detection wavelength: 254 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile gradient for liquid chromatography: 5%-95% solvent [B] linear gradient in 17 minutes, followed by 3 minutes, 95 % solvent [B] was maintained.
Flow rate: 1.0 mL/min Injection volume: 10 μL
(Measurement condition 7)
Column: Xselect CSH Fluoro-Phenyl (3.5 μm id 4.6×150 mm) (Waters)
Column temperature: constant temperature around 40°C UV detection wavelength: 255 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile gradient for liquid chromatography: 6 minutes, 20% solvent [B] maintained, 20%-42% solvent [B] for 21 minutes ], followed by a linear gradient of 42%-50% solvent [B] over 4 minutes, and finally a linear gradient of 50%-95% solvent [B] over 3 minutes.
Flow rate: 1.0 mL/min Injection volume: 10 μL
(Measurement condition 8)
Column: Xselect CSH Fluoro-Phenyl (3.5 μm id 4.6×150 mm) (Waters)
Column temperature: constant temperature around 40°C UV detection wavelength: 255 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is acetonitrile for liquid chromatography Gradient: 2 minutes, 20% solvent [B] maintained, 6 minutes 20%-37% solvent [B ], a linear gradient of 37%-50% solvent [B] was performed in 10 minutes, and a linear gradient of 50%-95% solvent [B] was performed in 2 minutes.
Flow rate: 1.0 mL/min Injection volume: 10 μL
(Measurement condition 9)
Column: YMC Jsphere ODS-H80 (4 μm id 4.6×250 mm)
Column temperature: constant temperature around 40°C UV detection wavelength: 250 nm
Mobile phase: [A] is an aqueous solution containing 0.2% trifluoroacetic acid, [B] is a methanol gradient for liquid chromatography: 10%-70% solvent [B] linear gradient in 6 minutes, followed by 3 minutes , maintain 70% solvent [B], then 70%-90% linear gradient in 3 minutes, then maintain 90% solvent [B] in 5 minutes, then linear 90%-95% in 1 minute Gradient followed by 5 min, maintaining 95% solvent [B] Flow rate: 1.0 mL/min Injection volume: 5 μL
(Measurement condition 10)
Column: Xselect CSH C18 (3.5 μm id 4.6×150 mm)
Column temperature: constant temperature around 40°C UV detection wavelength: 254 nm
Mobile phase: [A] is an aqueous solution containing 0.1% formic acid, [B] is an acetonitrile gradient for liquid chromatography: After performing a linear gradient of 5%-95% solvent [B] in 17 minutes, 3 minutes, 95 Maintain % solvent [B] Flow rate: 1.0 mL/min Injection volume: 10 μL
(Measurement condition 11)
Column: XBridge C18 (3.5 μm id 4.6×150 mm)
Column temperature: constant temperature around 40°C UV detection wavelength: 210 nm
Mobile phase: [A] is an aqueous solution containing 10 mM ammonia, [B] is a methanol gradient for liquid chromatography: 5% solvent [B] maintained in 5 minutes, 5%-38% solvent [B] linear in 10 minutes A gradient was run, a linear gradient from 38%-95% solvent [B] in 5 minutes.
Flow rate: 0.8 mL/min Injection volume: 10 μL

(Measurement of powder X-ray diffraction pattern)
The powder X-ray diffraction measurement of the crystals obtained in each example was performed according to the powder X-ray diffraction measurement method described in the Japanese Pharmacopoeia General Test Methods. Measurement conditions are shown below.
(Device)
Rigaku MiniFlex600
(Method of operation)
Detector: High-speed one-dimensional detector (D/TecUltra2)
Type of light source: Cu tube Wavelength used: CuKα ray Tube current: 15mA
Tube voltage: 40Kv
Sample plate: Non-reflective sample plate

(Measurement and analysis method for single crystal structure analysis)
The measurement conditions and analysis method for single crystal structure analysis are shown below.
(Device)
Rigaku XtaLAB P200 MM007
(Measurement condition)
Measurement temperature: 25°C
Wavelength used: CuKα rays (λ = 1.5418 Å)
Software: CrysAlisPro 1.171.39.46e (Rigaku Oxford Diffraction, 2018)
(Data processing)
Software: CrysAlisPro 1.171.39.46e (Rigaku Oxford Diffraction, 2018)
The data were Lorentz-, polarization-, and absorption-corrected.
(Crystal structure analysis)
Phase determination was performed using the direct method program ShelXT (Sheldrick, G.M., 2015), and refinement was performed using ShelXL (Sheldrick, G.M., 2015) using the full-matrix least-squares method. All temperature factors of non-hydrogen atoms were anisotropically refined. Hydrogen atoms were introduced by calculation using the default parameters of ShelXL and treated as riding atoms. All hydrogen atoms were refined with isotropic parameters.
PLATON (Spek, 1991)/ORTEP (Johnson, 1976) was used for the drawing of FIG.

Synthesis of Fumaric Acid Co-Crystal Form I of Compound of Formula (VII)

Step 1: Synthesis of Compound 3 Compound 1 (35.0 kg, 238.8 mol, hydrochloride), N,N-dimethylacetamide (273 L), 1,8-diazabicyclo[5,4,0]-7-undecene (87 .2 kg, 573.1 mol) and compound 2 (26.0 kg, 262.7 mol) were mixed and stirred at 25° C. for 10 minutes. N,N'-Carbonyldiimidazole (50.3 kg, 310.4 mol) and N,N-dimethylacetamide (7 L) were mixed with the reaction solution and stirred at 50°C for 90 minutes. Methanol (18.4 kg, 573.1 mol) was added to the reaction solution, cooled to 25° C., and adjusted to pH 2.5 with 10% sulfuric acid. The slurry was cooled to 5°C, the solid was collected by filtration, washed with 20% aqueous methanol, and dried to obtain compound 3 (38.12 kg, 162.0 mol, yield: 67.9%).
HPLC (UV = 254 nm): RT = 8.9 min, HPLC measurement condition 4

Step 2: Synthesis of compound 5 Compound 3 (34.5 kg, 146.7 mol), acetonitrile (345 L), diisopropylethylamine (26.5 kg, 205.4 mol) and compound 4 (39.6 kg, 176.0 mol) were mixed. , 60° C. for 300 minutes. The reaction solution was cooled to 25° C. and water (172.5 L) was added. The slurry was cooled to 0° C., the solid was collected by filtration, washed with 66% acetonitrile water, and dried to obtain compound 5 (46.10 kg, 121.5 mol, yield: 82.9%).
HPLC (UV = 254 nm): RT = 14.7 min, HPLC measurement condition 4

Step 3: Synthesis of compound 7 Compound 5 (29.0 kg, 76.4 mol), trifluoroacetic acid (72.5 L) and compound 6 (16.5 kg, 152.9 mol) were mixed and stirred at 35°C for 180 minutes. . The reaction solution was cooled, ethyl acetate (348 L) was added, and the mixture was washed with 38% aqueous tripotassium phosphate solution, 2.3% brine and water. The ethyl acetate solution was concentrated to 203 L and heptane (261 L) was added. The slurry was cooled to 0° C., the solid was collected by filtration, washed with a mixed solvent of ethyl acetate and heptane, and dried to obtain compound 7 (23.60 kg, 65.0 mol, yield: 85.0%). rice field.
HPLC (UV = 254 nm): RT = 12.5 min, HPLC measurement condition 5

Step 4: Synthesis of compound 9 Compound 7 (23.3 kg, 64.1 mol), compound 8 (14.0 kg, 83.4 mol, hydrochloride), potassium iodide (6.4 kg, 38.5 mol), cesium carbonate ( 31.3 kg, 96.2 mol) and N,N-dimethylacetamide (139.8 L) were mixed and stirred at 40° C. for 360 minutes. The reaction solution was cooled to 25° C. and acetic acid (34.6 kg, 577.2 mol) was added. Insoluble matter was filtered off, and acetonitrile (93.2 L) and water (326.2 L) were added to the filtrate. The slurry was cooled to 0° C., the solid was collected by filtration, washed with a 20% aqueous acetonitrile solution, and dried to obtain compound 9 (20.35 kg, 44.4 mol, yield: 69.2%).
HPLC (UV = 255 nm): RT = 25.1 min, HPLC measurement condition 7

Step 5: Synthesis of Fumaric Acid Co-Crystal Form I of Compound of Formula (VII) Compound 9 (39.0 kg, 80.7 mol), Compound 10 (16.2 kg, 84.8 mol), 484.3 mol) and toluene (234 L) were mixed and stirred at 100° C. for 360 minutes. Toluene (390 L) was added and the resulting slurry was cooled to 25°C. The solid was collected by filtration and washed with acetone to obtain undried crystals of the compound of formula (VII).
Acetone (613.5 L) and water (109.2 L) were added to half of the obtained compound represented by the formula (VII) and dissolved at 50°C. The resulting solution was treated with activated carbon, acetone (150.2 L) and water (5.9 L) were added to the treated solution, and the mixture was concentrated to 702 L. The temperature of the concentrate was adjusted to 50° C., fumaric acid (4.6 kg, 72.6 mol), acetone (150.2 L) and water (5.9 L) were added and concentrated to 464 L. Acetone (78 L) was added to the concentrate, concentrated to 265 L, and acetone (19.5 L) was added. The slurry was thermostatted to 55° C. and stirred for 120 minutes longer. The slurry was cooled to 0° C. and the solid was collected by filtration, washed with acetone and dried. By repeating the same operation for the remaining half amount, fumaric acid co-crystal form I (41.68 kg, 64.3 mol, yield: 75.6%) of the compound represented by formula (VII) was obtained.
HPLC (UV = 255 nm): RT = 12.8 min, HPLC measurement condition 8

Synthesis step 1 of toluene solute of compound represented by formula (VII)
Compound 9 (150 mg, 0.327 mmol) and compound 10 (65.4 mg, 0.360 mmol) were mixed with toluene (1.5 mL) and acetic acid (0.187 ml, 3.27 mmol) and stirred at 100°C for 9 hours. . After cooling to room temperature, heptane (1.5 mL, 10 V) was added and filtered, and the obtained crystals were washed with heptane (0.7 mL) three times. Drying under reduced pressure gave crystals of the compound represented by formula (VII) (168 mg, yield 87%). The obtained crystals contained 0.5 to 0.6 molecules of toluene as a solvate, and the toluene was not removed under reduced pressure drying in the normal operating range. It was confirmed that the toluene solute of the compound represented by formula (VII) was obtained in good quality.
1H-NMR (400 MHz, CDCl ₃ ) δ ppm: 7.93 (s, 1H), 7.70 (d, J = 2.57 Hz, 2H), 7.62 (brs, 1H), 7.35-7 , 45 (m, 1H), 7.07 (m, 1H), 6.92-6.97 (td, J = 9.63, 6.42, 1H), 5.34 (s, 2H), 5 .14 (s, 2H), 4.20 (s, 3H), 3.87 (s, 2H).
Peaks corresponding to 0.5 to 0.6 toluene molecules were confirmed at 7.14-7.27 ppm and 2.35 ppm.

Reference Example 1 Synthesis of Compound S-4

Step 1: Synthesis of Compound S-2 Compound S-1 (5.50 kg, 29.5 mol), acetonitrile (21.7 kg) and glacial acetic acid (115.00 kg) were mixed and cooled to 5°C. A 17% sodium nitrite aqueous solution (13.03 kg) was added, and the mixture was stirred for 1 hour, heated to 25°C, and stirred for 1.5 hours. The insoluble matter was filtered off and washed with acetonitrile (21.7 kg) and tetrahydrofuran (49.0 kg). Water (460 L) was added to the collected filtrate. The slurry was cooled to 0° C., the solid was collected by filtration, washed with water, and dried to obtain compound S-2 (3.75 kg, 19.0 mol, yield: 64.4%).
LC/MS (ESI): m/z = 196 (MH), RT = 11.8 min, LC/MS measurement condition 4

Step 2: Synthesis of Compound S-3 Compound S-2 (3.25 kg, 16.4 mol) and ethyl acetate (58.7 kg) were mixed, and trimethyloxonium tetrafluoroborate (2.09 kg, 14.1 mol) was added. and stirred at 25° C. for 7 hours. A mixture of ethyl acetate (29.5 kg) and methanol (10.3 kg) was added to the reaction solution. This mixture was added to a 5% aqueous sodium carbonate solution (66.3 kg) to separate into an organic layer and an aqueous layer. The organic layer was washed twice with 5% aqueous sodium chloride solution (65.8 kg), treated with activated carbon, and concentrated to 42 kg. An operation of adding tetrahydrofuran (87.0 kg) and concentrating to 23 kg was repeated twice, further adding tetrahydrofuran (87.0 kg), concentrating to 18.9 kg, and heating to 33°C. Heptane (47.0 kg) was added to this mixture. The slurry was cooled to 0° C., the solid was collected by filtration, washed with a mixture of tetrahydrofuran and heptane, and dried to give Compound S-3 (1.68 kg, 7.9 mol, yield: 48.2%). Obtained.
LC/MS (ESI): m/z = 212 (M+H), 253 (M+ _CH3CN +H) RT = 12.4 min, LC/MS measurement condition 4

Step 3: Synthesis of compound S-4 Compound S-3 (1040 g, 4.9 mol), 10% palladium carbon (PE type, hydrous) (523 g, 0.25 mol) and ethyl acetate (8.99 kg) are mixed, Hydrazine monohydrate (504 g, 10.1 mol) was added and stirred at 35° C. for 3 hours. The 10% palladium on carbon was filtered off and washed with water (1560 g) and ethyl acetate (9.00 kg). 2 mol/L hydrochloric acid (750 g) was added to the collected filtrate to separate into an organic layer and an aqueous layer. The resulting aqueous layer was extracted with ethyl acetate (4.69 kg). The organic layers were combined, treated with activated carbon, and concentrated to 11.09 kg. A 4 mol/L hydrogen chloride/ethyl acetate solution (1124 g) was added to this concentrate. The solid was collected by filtration, washed with ethyl acetate, and dried to obtain compound S-4 (0.84 kg, 3.9 mol, yield: 78.5%).
LC/MS (ESI): m/z = 182 (M+H), 223 (M+ _CH3CN +H) RT = 6.6 min, LC/MS measurement condition 4
Chlorine concentration (ion chromatography): 16.74%

Reference Example 2 Synthesis of Compound 8

Step 1: Synthesis of Dichloromethane Solution of Compound A-2 Compound A-1 (9.2 kg, 65.1 mol) and tetrahydrofuran (64 L) were mixed and cooled to 0° C. to form slurry. A Red-AL/tetrahydrofuran solution obtained by mixing sodium bis(2-methoxy)aluminum hydride (Red-AL)/toluene solution (65 wt%) (26.4 kg, 84.9 mol) and tetrahydrofuran (28 L) was contained therein. It was added dropwise over 60 minutes while maintaining the temperature at 8°C or lower. After that, the mixture was stirred at 0°C to 5°C for 30 minutes. Acetone (4.9 kg, 84.3 mol) was added dropwise to this reaction solution over 30 minutes, and the temperature was raised to 25°C. A slurry of potassium sodium tartrate tetrahydrate (46 kg, 163 mol) and tetrahydrofuran (138 L) was prepared in another reactor, and the reaction solution obtained by quenching the previous Red-AL reduction with acetone was added dropwise over 30 minutes. (During this time, the internal temperature reached around 40°C). Stirring was continued at 40°C for 2 hours and then cooled to 25°C. After adding water (2.5 kg) and stirring, Buchner filtration was performed, and the obtained filtrate was concentrated under reduced pressure to 35 kg (28 L). The filtrate (28 L) was divided into 3 equal portions, toluene (2.6 kg) was added to the first portion, and the operation of concentrating under reduced pressure was repeated 8 times, and finally concentrated to dryness. Dichloromethane (13.5 kg) was added to the concentrated and dried product to obtain a dichloromethane solution of product A-2. The same operation was performed for the second and third batches to prepare an A-2/dichloromethane solution composed of A-2 (5.53 kg) and dichloromethane (42.7 kg) (yield: 74.8 %).
1H-NMR (400MHz, CDCl3, 30°C) δ ppm: 8.00 (s, 1H), 4.74 (s, 2H), 3.90 (s, 3H).

Step 2: Synthesis of Compound 8 Dichloromethane (44 L) was added to the A-2/dichloromethane solution (49.8 kg of a dichloromethane solution containing 5.53 kg of A-2 (48.8 mol)) prepared in Step 1, and the mixture was heated to 25°C. temperature adjusted. A mixed solution of thionyl chloride (7.8 kg, 65.5 mol) and dichloromethane (27 L) was added dropwise over 30 minutes, and the line was washed with dichloromethane (8.2 L). bottom. Separately, a 20% sodium acetate aqueous solution (179 kg) was prepared from sodium acetate (36.2 kg, 436 mol) and tap water (143 L). 20% sodium acetate (119 kg) was added dropwise to the previous reaction solution. The pH at the end of dropping was around 4.6. The organic layer obtained by this operation was washed with a 10% sodium chloride aqueous solution prepared from sodium chloride (5.5 kg) and tap water (49 L), and the aqueous layer was also extracted with dichloromethane (55 L). After concentrating the combined organic layers (dichloromethane solution) to 33 L, ethyl acetate (27.5 L) was added and concentrated. After concentrating to 33 L, ethyl acetate (47.5 L) was added again, the mixture was concentrated under normal pressure at a jacket temperature of 60° C., and the resulting inorganic salt was filtered off. A hydrochloric acid/ethyl acetate solution (4 mol/L, 12.6 kg) was added to the filtrate for hydrochlorination, and after stirring at 25°C for 30 minutes, it was cooled to around 5°C. After stirring for 30 minutes and ripening for crystallization, the obtained crystallization slurry was filtered, washed with cooled ethyl acetate (55 L) and dried under reduced pressure to obtain compound 8 (5.25 kg) (pale yellow powder, yield rate: 64.8%).
1H-NMR (400MHz, DMSO-D6, 30°C) δ ppm: 8.54 (s, 1H), 4.70 (s, 2H), 3.86 (s, 3H).

Reference Example 3 Synthesis of compound 10

Step 1: Synthesis of compound B-2 Compound B-1 (79.1 kg, 499 mol) was added in portions to 98% sulfuric acid (395.7 L) cooled to 0°C to 5°C under a nitrogen atmosphere. (Keep the internal temperature between 0°C and 5°C). Potassium nitrate (55.5 kg) was kept at an internal temperature of 0° C. to 12° C. and charged in 15 portions (at intervals of 20 minutes or longer). The mixture was stirred at an internal temperature of 0°C to 5°C for 5 hours. The above reaction solution was slowly poured into water (791 L) cooled to 0°C to 5°C while maintaining the internal temperature at 0°C to 5°C, and washed with 98% sulfuric acid (39.6L). The mixture was stirred at 0°C for 5 hours. The slurry was centrifuge filtered and washed with water (791 L). The obtained crude solid was suspended in water (791 L) and stirred at 20° C. to 30° C. for 30 minutes, then the solid was filtered, washed with water (791 L) three times, dried under reduced pressure, and compound B-2. (99.61 kg) was obtained.
1H-NMR (400 MHz, CDCl3) δ ppm: 10.31 (s, 1H), 8.46 (d, J = 6.60 Hz, 1H), 7.47 (d, J = 9.17 Hz, 1H).
HPLC (UV = 250 nm): RT = 10.9 min, HPLC measurement condition 9

Step 2: Synthesis of compound S-2 Ethanol (697 L), water (697 L) and hydrazine monohydrate (73.5 kg, 1468 mol) were mixed and heated to 45°C. A mixed solution of compound B-2 (99.6 kg, 489 mol) and ethanol (299 L) was added dropwise thereto over 60 minutes, followed by stirring for 8 hours at 45° C. to 50° C. for 9 hours. An aqueous solution prepared from potassium hydrogen carbonate (53.9 kg, 538 mol) and water (1295 L) was added dropwise over 30 minutes while maintaining the internal temperature at 40°C to 50°C. After cooling to 0° C. to 5° C. and stirring for 1 hour, filtration was carried out. Water (1335 L) and ethanol (657 L) were mixed and the previous solid was washed with an aqueous ethanol solution cooled to 0°C to 5°C. After drying under reduced pressure, compound S-2 (83.25 kg) was obtained (yield: 86.9%).
1H-NMR (400MHz, DMSO-d6) δ ppm: 13.56-13.98 (m, 1H), 8.67 (s, 1H), 8.37 (d, J = 0.98Hz, 1H), 7.92 (d, J=0.61, 1H).
HPLC (UV = 250 nm): RT = 10.4 min, HPLC measurement condition 9

Step 3: Synthesis of compound S-3 Compound S-2 (84 kg, 430 mol) and ethyl acetate (1596 L) were mixed and stirred at 20°C to 30°C. Trimethyloxonium tetrafluoroborate (77.6 kg, 525 mol) was charged in several portions, ethyl acetate (84 L) was added, and the mixture was stirred at 25°C for 6 hours. A mixed solution of methanol (252 L) and ethyl acetate (420 L) was added dropwise to the above reaction solution over 2 hours to quench excess trimethyloxonium tetrafluoroborate. To an aqueous solution of sodium carbonate (84 kg) and water (1596 L) mixed, the above quenched reaction solution was added dropwise over 1 hour, and ethyl acetate (420 L) and methanol (84 L) were added. The organic layer obtained by the liquid separation operation was washed twice with saturated saline (1680 kg), and the obtained organic layer was filtered with activated carbon. Thereafter, after the organic layer was concentrated under reduced pressure, tetrahydrofuran (2520 L) was poured thereinto and further concentrated under reduced pressure. After adding tetrahydrofuran and concentrating under reduced pressure again, heptane (2139 L) was added dropwise, cooled to -5°C to 5°C, stirred at around 0°C for 1 hour, and subjected to crystallization and ripening. The crystallization slurry was filtered and washed with a cooled mixed solution of tetrahydrofuran (224 L) and heptane (912 L). After drying under reduced pressure, compound S-3 (65.73 kg) was obtained (yield: 74.1%).
1H-NMR (400 MHz, CDCl3) δ ppm: 8.31 (s, 1H), 8.13 (s, 1H), 7.81 (s, 1H), 4.27 (s, 3H).
HPLC (UV = 254 nm): RT = 10.3 min, HPLC measurement conditions 10

Step 4: Synthesis of Compound 10 Compound S-3 (65.7 kg, 310 mol) and ethyl acetate (657 L) were mixed, stirred at room temperature, cooled to around 10° C., and purged with nitrogen. 5% platinum-carbon (57.7 kg, 53% moisture content) was added. After purging with hydrogen, the mixture was stirred for 4 hours while adjusting the internal temperature to around 25°C. After confirming the disappearance of the raw material, nitrogen replacement and filtration were performed to remove the platinum-carbon catalyst. After liquid separation, the organic layer was concentrated, and heptane was added dropwise to the ethyl acetate solution to form a crystallization slurry. After filtration and washing with heptane/ethyl acetate, it was dried under reduced pressure to obtain compound 10 (37.24 kg) (yield: 66.2%).
1H-NMR (400 MHz, CDCl3) δ ppm: 7.70 (s, 1H), 7.64 (s, 1H), 6.89 (s, 1H), 4.15 (s, 3H).
HPLC (UV = 254 nm): RT = 4.8 min, HPLC measurement conditions 10

Reference Example 4 Synthesis of Compound 9

Step 1: Synthesis of compound C-2 Compound C-1 (10.00 g, 48.0 mmol, mesylate), N,N'-carbonyldiimidazole (8.18 g, 50.4 mmol), acetonitrile (60.00 mL ), and diisopropylethylamine (6.83 g, 52.8 mmol) were mixed and stirred at 10° C. for 60 minutes. Compound 1 (8.09 g, 55.2 mmol, hydrochloride) and diisopropylethylamine (7.14 g, 55.2 mmol) were mixed with the reaction solution and stirred at 50° C. for 210 minutes. The reaction was cooled and concentrated to 45 g. After adding 2-propanol (100 mL) and concentrating to 60 g, 2-propanol (100 mL) was added. The slurry was cooled to 0° C., the solid was collected by filtration, washed with 2-propanol, and dried to obtain compound C-2 (10.48 g, 42.2 mmol, yield: 88%).
HPLC (UV = 210 nm): RT = 14.5 min, HPLC measurement condition 11

Step 2: Synthesis of Compound C-3 Compound C-2 (8.00 g, 32.2 mmol), N,N'-carbonyldiimidazole (6.79 g, 41.9 mmol), tetrahydrofuran (80.0 mL), and 1 ,8-diazabicyclo[5,4,0]-7-undecene (5.40 g, 35.4 mmol) was mixed and stirred at 25° C. for 120 minutes. Tetrahydrofuran (80.0 mL) was added dropwise and the reaction was cooled to 0° C. to form a crystallization slurry. The solid was collected by filtration, washed with tetrahydrofuran, and dried by heating to give crystals of Compound C-3 (12.6 g, 29.6 mmol, 1,8-diazabicyclo[5.4.0]-7-undecene salt). yield: 92%).
HPLC (UV = 210 nm): RT = 1.9 min, HPLC measurement condition 11

Step 3: Synthesis of Compound 9 Compound C-3 (1.00 g, 2.3 mmol, 1,8-diazabicyclo[5.4.0]-7-undecene salt), N,N-dimethylacetamide (5.0 mL) , and compound 4 (579.2 mg, 2.6 mmol) were mixed and stirred at 70° C. for 300 minutes. The operation of cooling the reaction solution, adding acetonitrile (10 mL), and concentrating to 9.4 g was repeated twice. Compound 6 (461 mg, 4.7 mmol) and diisopropylethylamine (456 mg, 3.5 mmol) were added to the concentrate and stirred at 60°C for 160 minutes. The reaction was cooled to 25°C, acetic acid (703 mg, 11.7 mmol), water (8.0 mL) and seed crystals were added and the resulting crystallization slurry was cooled to 0°C. Water (12.0 mL) was added to the slurry, the solid was collected by filtration, washed with a 20% aqueous acetonitrile solution, and dried to obtain compound 9 (0.86 g, 1.9 mmol, yield: 79.5%). rice field.
HPLC (UV = 255 nm): RT = 14.5 min, HPLC measurement condition 8

Reference Example 5 Synthesis of Compound S-3

Step 1: Synthesis of Compound S-3 Compound B-2 was obtained in the same manner as in Step 1 of Reference Example 3. Subsequently, compound B-2 (30 g, 147 mmol) and NMP (120 mL) were mixed, 1-Boc-1-methylhydrazine (56 g, 383 mmol) was added under ice-cooling, and the mixture was stirred at room temperature for 30 minutes. Diisopropylethylamine (38.6 mL, 221 mmol) was added to the reaction solution, and the mixture was stirred at 90° C. for 20 hours. After the reaction solution was brought to 80° C. and water (240 mL) was added, the solution was cooled to room temperature and the precipitated insoluble matter was separated by filtration. The obtained solid was washed with a mixed solution of NMP/water=1/2 (15 mL) three times, and further washed with water (30 mL) three times. The resulting solid was suspended in isopropyl acetate (60 mL) and heptane (240 mL), stirred at room temperature, and washed three times with isopropyl acetate/heptane=1/4 (30 mL) to obtain compound D-3. The resulting solid was suspended in isopropyl acetate (100 mL). The resulting suspension was added to a mixture of mesylic acid (96 mL, 1474 mmol) and isopropyl acetate (100 mL) at 55°C, washed with isopropyl acetate (60 mL), and stirred at the same temperature for 25 minutes. Water (240 mL), aqueous sodium hydroxide solution (239 mL, 1916 mmol) and isopropyl acetate (150 mL) were added to the reaction solution under ice-cooling, and the mixture was stirred at 40°C. Isopropyl acetate (150 mL) was added to the resulting reaction solution. The resulting organic layer was washed with water (90 mL) three times and concentrated to 45 g. Isopropyl acetate (12 g) and heptane (210 mL) were added, the obtained insoluble matter was filtered off, and the solid was washed three times with isopropyl acetate/heptane=1/7 (30 ml) and dried to give Compound S-3. (25.3 g, 120 mmol, yield: 81.1%) was obtained.
1H-NMR (400 MHz, CDCl3) δ ppm: 8.34 (s, 1H), 8.13 (s, 1H), 7.84 (s, 1H), 4.28 (s, 3H).

Reference Example 6 Synthesis of Compound 10

Step 1: Synthesis of Compounds T-2 and T-3 Under ice-cooling, compound T-1 (40 g, 182 mmol), concentrated sulfuric acid (200 mL, 3677 mmol) and 69% nitric acid (23.3 g, 255 mmol) were mixed and mixed with ice. The mixture was stirred from cold to room temperature for 3 hours and then allowed to stand overnight. The mixed liquid was poured into 520 mL of ice water, and dichloromethane (200 mL) was added to perform a liquid separation operation. The resulting dichloromethane solution was washed twice with 5% aqueous sodium bicarbonate solution (400 mL) and concentrated to dryness. Methanol (120 mL) was added to the resulting solid, and the mixture was concentrated until the content reached 116 g. After adding methanol to the obtained slurry until the content reaches 333 g, water (240 mL) is added, the obtained insoluble matter is filtered off, and the solid is washed with methanol / water = 1/1 (200 mL), By drying, a mixture of compounds T-2/T-3=1/2.78 (30.67 g, yield: 58.5%) was obtained.
LC/MS (ESI): MS not detected as m/z, RT = 2.04 min, LC/MS measurement condition 1

Step 2: Synthesis of compound T-4 Under a nitrogen stream, 2-propanol (1.4 mL) was added to a mixture of T-2/T-3 = 1/2.78 (200 mg), and the temperature was raised to 60°C. Triethylamine (0.289 mL, 2.07 mmol) was added and stirred for 1.5 hours. After that, a solution of methylamine hydrochloride (94 mg, 1.39 mmol) in water (0.4 mL) was added to the reaction solution at 60° C. and stirred for 3 hours. After water (8 mL) was added to the obtained reaction solution at 60° C., the solution was cooled to room temperature and stirred for 30 minutes. The precipitated insoluble matter was filtered off, and the resulting solid was washed with water (5 mL) and dried to obtain compound T-4 (194 mg, 0.699 mmol, yield: 100%).
LC/MS (ESI): m/z = 277 (M + H), RT = 2.46 min, LC/MS measurement condition 2

Step 3: Synthesis of Compound T-5 Compound T-4 (500 mg, 1.80 mmol), 2-propanol (2.5 mL) and tributylphosphine (802 mg, 3.96 mmol) were mixed under a nitrogen stream, and heated to 80°C. The mixture was stirred for 1.5 hours. After cooling to room temperature, solvent replacement was performed three times with toluene (3 mL), and concentration was performed until the residue after concentration was 5 g. Thereafter, the reaction solution was ice-cooled to 4° C., 4 mol/L hydrochloric acid-ethyl acetate solution (1.5 mL) was added, and the mixture was stirred for 20 minutes. The resulting crystallization slurry was filtered, washed with toluene (2.5 mL), and dried to obtain a solid. The resulting solid was added portionwise to a mixture of water (4.3 mL) and sodium bicarbonate (0.192 g, 2.29 mmol), the pH was adjusted to 7-8 and stirred for 30 minutes to form a crystallization slurry. Obtained. By filtering, washing with water (8.6 mL) and drying, compound T-5 (351 mg, 1.43 mmol, yield: 79.4%) was obtained.
LC/MS (ESI): m/z = 245 (M + H), RT = 1.90 min, LC/MS measurement condition 1

Step 4: Synthesis of Compound 10 Compound T-5 (2.015 g, 8.21 mmol), DME (20 mL), sodium tert-butoxide (1.104 g, 11.49 mmol), benzophenone imine (1.645 mL) under a nitrogen stream. , 9.80 mmol), BINAP (0.153 g, 0.246 mmol), and diacetoxypalladium (0.036 g, 0.160 mmol) were mixed and stirred at 80° C. for 9 hours and allowed to stand overnight. Ethanol (10 mL) was added to the resulting suspension and cooled to 5°C. 30% sulfuric acid (20 mL) was added little by little to the suspension, and the mixture was stirred overnight at room temperature. Ethyl acetate (40 mL) and water (20 mL) were added to the obtained reaction solution to carry out a liquid separation operation. The resulting aqueous layer was washed with ethyl acetate (10 mL), and the organic layer was washed with 10% sulfuric acid (10 mL). The resulting aqueous layers were combined, cooled with ice, and then neutralized to pH 8 using a 48% sodium hydroxide aqueous solution. Ethyl acetate (20 mL) was added, the precipitated sodium sulfate was filtered off, and a liquid separation operation was performed. Ethyl acetate (20 mL) was added to the resulting aqueous layer to carry out a liquid separation operation. The obtained organic layers were combined, concentrated, and solvent replacement was repeated four times with ethyl acetate (10 mL). Heptane (12 mL) was added, and the resulting crystallization slurry was stirred under ice-cooling for 1 hour. By filtering, washing with ethyl acetate/heptane=1/3 (6 mL) and drying, compound 10 (1.18 g, 6.5 mmol, yield: 79.2%) was obtained.
LC/MS (ESI): m/z = 182 (M + H), RT = 0.88 min, LC/MS measurement condition 1

Reference Example 7 Synthesis of Compound U-4

Step 1: Synthesis of compound U-2 Compound U-1 (2.09 g, 22.6 mmol, hydrochloride) was mixed with CPME (12.04 g) and water (7 g), and potassium carbonate (4.25 g, 30. 8 mmol) dissolved in water (7 g) was added slowly so that the temperature of the reaction solution reached 20-30°C. The resulting mixed solution was vigorously stirred, CbzCl (3.50 g, 20.5 mmol) was added slowly so that the temperature of the reaction solution reached 20 to 30° C., and the mixture was stirred at room temperature for 1 hour. The resulting solution was subjected to liquid separation, and the organic layer was washed with water (14 g) and then concentrated. CPME (15.05 g) was added to the residue and further concentrated to 10.5 g of residue. The resulting solution was warmed to 45° C. and heptane (9.58 g) was added over 30 minutes while maintaining the temperature, followed by stirring for an additional 30 minutes. After adding heptane (19.15 g), the resulting crystallization slurry was stirred for 30 minutes under ice cooling. The obtained solid was filtered off, washed with a mixture of CPME-heptane (3 g-9.58 g), and dried to obtain compound U-2 (3.41 g, 17.93 mmol, yield: 86%). rice field.
HPLC (UV = 254 nm): RT = 9.51 min, HPLC measurement condition 5

Step 2: Synthesis of compound U-3 Methanol (31.66 g) was added to compound U-2 (8.00 g, 42.1 mmol), and after cooling to 0°C, a 28% methanol solution of sodium methoxide (2.43 g , 12.6 mmol) was added, and the mixture was stirred at the same temperature for 4 hours. To the resulting solution was added a solution of N-methylformohydrazide (3.74 g, 50.5 mmol) in methanol (19 g) at 0-5°C, and acetic acid (2.53 g, 42.1 mmol) was added to the same. added at room temperature and stirred at 0° C. for 2 hours. The obtained solution was heated to 60° C. and stirred at the same temperature for 4 hours. After concentrating the reaction solution to 32 g, ethyl acetate (57.73 g) and 5% aqueous sodium hydrogencarbonate solution (67.53 g) were added. The obtained mixed solution was stirred for 10 minutes to perform a liquid separation operation. The resulting aqueous layer was also extracted with ethyl acetate (57.73 g). The combined organic layers were concentrated to 40 g. The operation of adding MEK (64.4 g) and further concentrating to 40 g was repeated twice. A solution of mesylic acid (4.04 g, 42.0 mmol) dissolved in MEK (32.2 g) was added to the resulting concentrate at 20-30° C., and the mixture was stirred at room temperature for 30 minutes. The precipitated crystallization slurry was filtered, and the resulting solid was washed with MEK (25.76 g) and dried to give compound U-3 (10.1 g, 29.5 mmol, mesylate, yield: 70 %) was obtained.
HPLC (UV = 254 nm): RT = 7.90 min, HPLC measurement condition 5

Step 3: Synthesis of Compound C-1 Compound U-3 (10 g, 29.2 mol, mesylate) and methanol (79.15 g) were mixed, stirred at room temperature, and then purged with nitrogen. Palladium-carbon (10% palladium) (0.5 g, 5% by weight) was added, and after purging with hydrogen, the mixture was stirred at room temperature for 7 hours. After purging with nitrogen, the palladium-carbon catalyst was removed by Celite (registered trademark) filtration. The obtained filtrate was concentrated to 50 g. The operation of adding MEK (40.25 g) and concentrating to 40 g was repeated twice. The obtained crystallization slurry was filtered, washed with MEK (25.76 g) and dried to obtain compound C-1 (5.3 g, 25.5 mmol, mesylate, yield: 87%). rice field.
HPLC (UV = 254 nm): RT = 2.75 min, HPLC measurement condition 11

（参考例８－１）
化合物７（４．００ｇ、１１．０ｍｍｏｌ）、化合物８（２．４０ｇ、１４．３ｍｍｏｌ、塩酸塩）、塩化リチウム（０．６１ｇ、１４．３ｍｍｏｌ）、トリエチルアミン（３．３４ｇ、３３．０ｍｍｏｌ）およびＮ，Ｎ－ジメチルアセトアミド（２０．０ｍＬ）を混合し、４０℃で１５時間攪拌した。反応溶液を２５℃に冷却し、酢酸（３．９７ｇ、６６．１ｍｍｏｌ）を加えた後、アセトニトリル（２０．０ｍＬ）、水（８．０ｍL）を加えて不溶物を溶解させた。その後、水（４８．０ｍL）を加えた後、０℃に冷却し、固体をろ取した。２０％アセトニトリル水溶液で洗浄後、乾燥することで化合物９（４．２８ｇ、９．３ｍｍｏｌ、収率：８４．８％）を得た。
ＨＰＬＣ（ＵＶ＝２５５ｎｍ）：ＲＴ＝２５．１ｍｉｎ、ＨＰＬＣ測定条件７ Reference Example 8 Synthesis of Compound 9

(Reference example 8-1)
compound 7 (4.00 g, 11.0 mmol), compound 8 (2.40 g, 14.3 mmol, hydrochloride), lithium chloride (0.61 g, 14.3 mmol), triethylamine (3.34 g, 33.0 mmol) and N,N-dimethylacetamide (20.0 mL) was mixed and stirred at 40° C. for 15 hours. After cooling the reaction solution to 25° C. and adding acetic acid (3.97 g, 66.1 mmol), acetonitrile (20.0 mL) and water (8.0 mL) were added to dissolve insoluble matter. Then, after adding water (48.0 mL), the mixture was cooled to 0° C. and the solid was collected by filtration. After washing with a 20% aqueous acetonitrile solution and drying, compound 9 (4.28 g, 9.3 mmol, yield: 84.8%) was obtained.
HPLC (UV = 255 nm): RT = 25.1 min, HPLC measurement condition 7

(Reference example 8-2)
Compound 7 (6.00 g, 16.5 mmol), Compound 8 (3.60 g, 21.4 mmol, hydrochloride), lithium chloride (0.94 g, 22.2 mmol), 1,8-diazabicyclo[5,4,0 ]-7-Undecene (6.13 g, 40.3 mmol) and N,N-dimethylacetamide (36.0 mL) were mixed and stirred at 40° C. for 7 hours. The reaction solution was cooled to 25° C., acetic acid (2.00 g, 33.3 mmol) and N,N-dimethylacetamide (1.8 mL) were added, followed by water (3.1 mL). After that, water (33.0 mL) was added and the solid was collected by filtration, washed with a 20% aqueous acetonitrile solution, and dried to obtain compound 9 (6.72 g, 14.7 mmol, yield: 88.8%). rice field.
HPLC (UV = 255 nm): RT = 25.1 min, HPLC measurement condition 7

ここで、Ｖｏｌｕｍｅは単位格子体積、Ｚは単位格子中の分子数を意味する。 The results of single crystal structure analysis of fumaric acid co-crystal form I of the compound represented by formula (VII) are shown below.
R1 (I>2.00 s(I)) was 0.0470, confirming neither missing nor misplaced electron densities from the final difference Fourier.
Crystallographic data are shown in Table 1.

Here, Volume means the unit cell volume and Z means the number of molecules in the unit cell.

In addition, Tables 2 and 3 show atomic coordinates of non-hydrogen atoms. Here, U(eq) means an equivalent isotropic temperature factor.

Next, Table 4 shows atomic coordinates of hydrogen atoms. Here, U(iso) means an isotropic temperature factor. Also, the numbers of the hydrogen atoms in Table 4 are associated with the numbers of the non-hydrogen atoms to which they are attached.

Further, Table 5 shows the interatomic bond distance (unit: angstrom).

In the fumaric acid co-crystal Form I of the compound of formula (VII), one molecule of the compound of formula (VII) was present in the asymmetric unit. The structure in the asymmetric unit of fumaric acid co-crystal Form I of the compound of formula (VII) is shown in FIG.
The numbers of non-hydrogen atoms in Tables 2 to 3 and Table 5 correspond to the numbers shown in FIG.

であると同定した。 As shown in Table 5, the bond distance of N10-C9 was about 1.26 Å, and the bond distance of N16-C9 was about 1.37 Å.
Since the N10-C9 bond distance (approximately 1.26 Å) is shorter than the N16-C9 bond distance (approximately 1.37 Å), the compound of formula (VII) in fumaric acid cocrystal form I has an imino structure :

identified as

In other words, even the same compound may have an imino structure or an amino structure depending on the crystallization conditions, etc., and even when a salt or complex is formed, the counter molecule of the salt or complex may be Depending on the type, it may have an imino structure or an amino structure, and even the same counter molecule may have an imino structure or an amino structure depending on the crystallization conditions and the like. It may also be a mixture of a compound having an imino structure, a salt thereof, or a complex thereof and a compound having an amino structure, a salt thereof, or a complex thereof.

1 shows the results of powder X-ray diffraction of fumaric acid co-crystal form I of the compound represented by formula (VII) obtained by the production method described in Example 1. FIG.
In powder X-ray diffraction pattern, diffraction angle (2θ): 7.7 ± 0.2 °, 9.5 ± 0.2 °, 10.0 ± 0.2 °, 10.9 ± 0.2 °, 13 .8±0.2°, 14.6±0.2°, 18.6±0.2°, 22.6±0.2°, 23.4±0.2° and 24.6±0. A peak was observed at 2°.
FIG. 2 shows the powder X-ray diffraction pattern of the fumaric acid co-crystal Form I of the compound of formula (VII). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).

Moreover, the result of the powder X-ray diffraction of the toluene salt of the compound represented by formula (VII) is shown.
In powder X-ray diffraction pattern, diffraction angle (2θ): 7.4 ± 0.2 °, 8.1 ± 0.2 °, 13.7 ± 0.2 °, 15.1 ± 0.2 °, 16 .3±0.2°, 19.3±0.2°, 21.4±0.2°, 22.6±0.2°, 24.6±0.2°, 26.6±0. Peaks were observed at 2°, 27.8±0.2° and 29.5±0.2°.
FIG. 3 shows the powder X-ray diffraction pattern of the toluene solute of the compound represented by formula (VII). The horizontal axis represents 2θ (°), and the vertical axis represents intensity (Count).
The molecular structure (amino body/imino body) of the toluene solute of the compound represented by formula (VII) has not been identified.

Biological test examples of the compounds produced by the production method according to the present invention are described below.
The compound represented by the formula (VII) according to the present invention has a coronavirus 3CL protease inhibitory action and may inhibit coronavirus 3CL protease.
Specifically, in the evaluation method described below, the _IC50 is preferably 50 μM or less, more preferably 1 μM or less, and still more preferably 100 nM or less.

Test Example 1-2: Cytopathic effect (CPE) suppression effect confirmation test using human TMPRSS2-expressing Vero E6 cells (Vero E6/TMPRSS2 cells) <Operating procedure>
- Dilution and dispensing of test sample A test sample is diluted with DMSO in advance to an appropriate concentration, and after preparing a 3-fold serial dilution series, it is dispensed into a 96-well plate.
・Dilution and dispensing of cells and SARS-CoV-2 VeroE6/TMPRSS2 cells (JCRB1819, 1.5×10 ⁴ cells/well) and SARS-CoV-2 hCoV-19/Japan/TY/WK-521/2020, hCoV-19/Japan/QK002/2020, hCoV-19/Japan/QHN001/2020, hCoV-19/Japan/QHN002/2020, hCoV-19/Japan/TY7-501/2021, hCoV-19/Japan/TY7- 503/2021, hCoV-19/Japan/TY8-612/2021, hCoV-19/Japan/TY11-927-P1/2021 (30-1000 TCID ₅₀ /well) in medium (MEM, 2% FBS, penicillin-streptomycin) After mixing with and distributing into the wells containing the test samples, culture in a CO ₂ incubator for 3 days.
Dispense of CellTiter-Glo (registered trademark) 2.0 and measurement of luminescence signal After returning the plate cultured for 3 days to room temperature, CellTiter-Glo (registered trademark) 2.0 is dispensed into each well, and the plate Mix with a mixer. After a certain period of time, the luminescence signal (Lum) is measured with a plate reader.

<Calculation of each measurement item value>
・ 50% SARS-CoV-2 infected cell death inhibitory concentration (EC ₅₀ ) calculation When x is the logarithmic value of the compound concentration and y is % Efficacy, the inhibition curve is approximated by the following Logistic regression equation, y = 50 ( %) is substituted and the value of x is calculated as _EC50 .

y = min + (max - min)/{1 + (X50/x)^Hill}

%Efficacy = {(Sample - virus control) / (cell control - virus control)} * 100%
cell control: the average of Lum of cell control wells
virus control: the average of Lum of virus control wells

min: lower limit of y-axis, max: upper limit of y-axis, X50: x coordinate of inflection point, Hill: slope of curve at midpoint between min and max

Compounds prepared by the method of preparation of the present invention were tested essentially as described above. The results are shown below.
(SARS-CoV-2 hCoV-19/Japan/TY/WK-521/2020)
Fumaric acid co-crystal form I of the compound of formula (VII): 0.37 μM

Test Example 2-2: SARS-CoV-2 3CL protease inhibitory activity test <Material>
・Commercially available Recombinant SARS-CoV-2 3CL Protease
- Commercially available substrate peptide Dabcyl-Lys-Thr-Ser-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-Lys-Met-Glu(Edans)-NH2 (SEQ ID NO: 1)
- Internal Standard peptide Dabcyl-Lys-Thr-Ser-Ala-Val-Leu(13C6,15N)-Gln (SEQ ID NO: 2)
Dabcyl-Lys-Thr-Ser-Ala-Val-Leu(13C6,15N)-Gln is described in the literature (Atherton, E.; Sheppard, R.C., "In Solid Phase Peptide Synthesis, A Practical Approach", IRL Press at Oxford University Press, 1989. and Bioorg. Med. Chem., Vol. An example is shown below.
H-Lys-Thr-Ser-Ala-Val-Leu(13C6,15N)-Glu(resin)-OαOtBu (Lys side chain is Boc protected, Thr side chain is protected with a tert-butyl group, the Ser side chain is protected with a tert-butyl group, the C-terminal OH of Glu is protected with a tert-butyl group, and the carboxylic acid of the Glu side chain is condensed with the resin). Modification of the N-terminal Dabcyl group involves condensation of 4-dimethylaminoazobenzene-4′-carboxylic acid (Dabcyl-OH) on the resin using EDC/HOBT. Final deprotection and cleavage from the resin are performed by treatment with TFA/EDT=95:5. It is then purified by reverse phase HPLC.
・Rapid Fire Cartridge C4 type A
<Operation procedure>
-Preparation of assay buffer In this test, an assay buffer consisting of 20 mM Tris-HCl, 1 mM EDTA, 10 mM DTT and 0.01% BSA is used.
-Dilution and dispensing of test sample A test sample is diluted in advance with DMSO to an appropriate concentration, and after preparing a 3-fold serial dilution series, it is dispensed into a 384-well plate.
Addition of Enzyme and Substrate, Enzyme Reaction Add 8 μM substrate and 6 nM enzyme solution to the prepared compound plate and incubate at room temperature for 3 hours. Thereafter, a reaction stop solution (0.072 μM Internal Standard, 0.1% formic acid, 10% acetonitrile) is added to stop the enzymatic reaction.
Measurement of Reaction Products Reaction completed plates are measured using a RapidFire System 360 and a mass spectrometer (Agilent, 6550 iFunnel Q-TOF). A solution (75% isopropanol, 15% acetonitrile, 5 mM ammonium formate) and B solution (0.01% trifluoroacetic acid, 0.09% formic acid) are used as mobile phases for measurement.
The reaction product detected by the mass spectrometer is calculated using RapidFire Integrator and taken as a Product area value. In addition, the internal standard detected at the same time is also calculated and used as the internal standard area value.
<Calculation of each measurement item value>
・P/IS is calculated by calculating the area value obtained in the item before calculating P/IS using the following formula.
P / IS = Product area value / Internal Standard area value 50% SARS-CoV-2 3CL protease inhibitory concentration (IC ₅₀ ) calculation When x is the logarithmic value of the compound concentration and y is % Inhibition, the following Logistic regression formula The inhibition curve is approximated with , and the value of x when y=50 (%) is substituted is calculated as _IC50 .

y = min + (max - min)/{1 + (X50/x)^Hill}

%Inhibition={1-(Sample-Control(-))/Control(+)-Control(-))}*100

Control (-): the average of P/IS ratio in the wells without SARS-CoV-2 3CL protease and test substance
Control (+): the average of P/IS ratio in the wells with SARS-CoV-2 3CL protease and without test substance

min: y-axis lower limit, max: y-axis upper limit, X50: x-coordinate of inflection point, Hill: slope of curve at midpoint between min and max

Compounds prepared by the method of preparation of the present invention were tested essentially as described above. The results are shown below.
Fumaric acid co-crystal form I of the compound of formula (VII): 0.0132 μM

The formulation examples shown below are merely illustrative and are not intended to limit the scope of the invention in any way.
The compounds produced by the process according to the invention can be administered by any conventional route, in particular enterally, e.g. orally, e.g. in the form of tablets or capsules, or parenterally, e.g. injectable solutions or suspensions. It can be administered as a pharmaceutical composition in the form of a cloud, topically, for example, in the form of a lotion, gel, ointment or cream, or in nasal or suppository form. A pharmaceutical composition comprising a compound produced by the production process according to the present invention in free form or in the form of a pharmaceutically acceptable salt, together with at least one pharmaceutically acceptable carrier or diluent, It can be manufactured in a conventional manner by mixing, granulating or coating methods. For example, oral compositions can be tablets, granules, capsules containing excipients, disintegrants, binders, lubricants, etc. and active ingredients. Injectable compositions may be in the form of solutions or suspensions, may be sterilized, and may contain preservatives, stabilizers, buffers and the like.

The compound produced by the production method according to the present invention has an inhibitory effect on coronavirus 3CL protease, and is thought to be useful as a therapeutic and/or prophylactic agent for diseases or conditions involving coronavirus 3CL protease. The novel synthetic intermediates or their salts according to the present invention and the production method according to the present invention are useful for pharmaceutical production.

Claims (18)

Formula (I):

(wherein R ¹ is substituted or unsubstituted C1-C4 alkyl, R ² is each independently halogen, cyano or methyl, and n is an integer of 1 to 5) or a salt thereof , formula (II):

(Wherein, each R ³ is independently a substituted or unsubstituted C1-C4 alkyl, and m is an integer of 0 to 5) or a salt thereof is reacted in the presence of an acid. and formula (III):

A method for producing a compound represented by or a salt thereof. 2. The production method according to claim 1, wherein the acid is trifluoroacetic acid. The compound represented by formula (III) is represented by formula (III-1):

The manufacturing method according to claim 1 or 2, wherein Formula (IV):

(Wherein, R ⁴ is a substituted or unsubstituted aromatic heterocyclic group or a substituted or unsubstituted aromatic carbocyclic group, p is 0 or 1, and other symbols are has the same meaning) or a salt thereof, and the formula (V):

(Wherein, each R ⁵ is independently a halogen or a substituted or unsubstituted alkyl, and q is an integer of 0 to 5) or a salt thereof is reacted in the presence of an acid. Formula (VI), characterized in that:

(The symbols in the formula have the same meanings as above.) A method for producing a compound represented by the formula, a salt thereof, or a solvate thereof. 5. The production method according to claim 4, wherein the acid is acetic acid. The compound represented by formula (VI) is
Formula (VII):

The manufacturing method according to claim 4 , wherein From the production method according to claim 1 , the formula (III-1):

A step of obtaining a compound of formula (VII) or a salt thereof:

A method for producing a compound represented by, a salt thereof, or a solvate thereof. Formula (VII):

or a salt thereof in the presence of fumaric acid, acetone and water. Formula (VII) obtained by using the process according to claim 7 :

The production method according to claim 8, characterized in that the compound represented by or a salt thereof is crystallized. The production method according to claim 9 , wherein the crystallization temperature is 40 to 60°C and the crystallization time is 120 minutes or longer. Formula (VIII):

A compound represented by or a salt thereof. Formula (IX):

A compound represented by or a salt thereof. Formula (X):

A compound represented by or a salt thereof. Formula (XI):

A compound represented by or a salt thereof. Formula (VII):

Toluene solute of the compound represented by. From the production method according to claim 3, formula (III-1):

A step of obtaining a compound of formula (VII) or a salt thereof:

A method for producing a compound represented by, a salt thereof, or a solvate thereof. Formula (VII) obtained by using the process according to claim 4:

The production method according to claim 8, characterized in that the compound represented by or a salt thereof is crystallized. Formula (VII) obtained by using the process according to claim 6:

The production method according to claim 8, characterized in that the compound represented by or a salt thereof is crystallized.

Images